U.S. Markets open in 9 hrs 20 mins

Biotech Industry Poised for a Breakout in 2017? Today's Reports on Cellect Biotechnology and XOMA

NEW YORK, NY / ACCESSWIRE / February 15, 2017 / Biotech stocks have continued to outperform the broader markets in 2017 as an easier regulatory environment and growing speculation of mergers & acquisitions speculation have combined to provide the potential for a breakout year for the industry. The iShares NASDAQ Biotechnology Index ETF and the SPDR S&P Biotech ETF have posted year-to-date gains of 9.2 percent and 14.9 percent, respectively, compared to gains of 3.75 percent and 4.41 percent for the Dow and the S&P 500.

Register today for a free membership and gain access to daily research reports at: RDInvesting.com

"We're also going to be streamlining the process, so that from your standpoint, when you have a drug you can actually get it approved, instead of waiting for many, many years," commented President Trump earlier this year on the current drug approval process. President Trump has vowed to reduce current FDA regulations by "75 to 80 percent".

"I'll oppose anything that makes it harder for smaller, younger companies to take the risk of bringing their product to a vibrantly competitive market," Trump said. "That includes price-fixing by the biggest dog in the market, Medicare, which is what's happening. But we can increase competition and bidding wars, big time."

Let's Take a Closer Look at Today's Trending Tickers

Cellect Biotechnology's shares surged 18.83 percent to close at $6.12 a share on Tuesday. The stock traded between $5.12 and $6.75 on volume of 1.56 million shares traded. On February 8th, the company reported that it has treated the first blood cancer patient in the Phase I/II trial of its stem cell technology ApoGraft.

Cellect CEO, Shai Yarkoni commented, "Enrolling our first cancer patient to be treated using our groundbreaking method is a critical milestone for millions of patients worldwide. ApoGraft has been proven to be effective in assisting successful stem cells transplants and preventing GvHD during our animal studies. I am excited with prospects of Cellect becoming a key contributor to the fast-growing market for stem cells based products enabling 21st century regenerative medicine."

Access Today's Cellect Biotechnology Research Report Click Here

XOMA's shares spiked 20.75 percent to close at $5.82 a share on Tuesday. The stock traded between $4.75 and $5.88 on volume 859,599 shares traded. On January 31st, the company announced that it has established proof-of-concept for its product candidate 358 in congenital hyperinsulinism (CHI) and hypoglycemia post-bariatric surgery (PBS).

"With the large unmet clinical need in patients with CHI and PBS, 358 provides a first-in-class antibody with the potential to help pediatric and adult patients properly regulate their blood glucose concentrations and prevent hypoglycemic episodes," said Eric P. Brass, M.D., Ph.D., Professor Emeritus of Medicine, David Geffen School of Medicine, University of California, Los Angeles.

On February 13, the company announced that it has agreed to sell 1.2 million of its common stock and 5,003 share of its convertible preferred stocks when converted to common stocks will result in 5,003,000 common stocks to Biotechnology Value Fund, L.P. and certain of its affiliates for total amount of $25.0 million at average price of $4.03 per common stock. The offering is expected to close on or about February 15, 2017.

Access Today's XOMA Research Report Click Here

Today's Features Includes:

Cellect Biotechnology Ltd. (NASDAQ: APOP)

XOMA Corporation (NASDAQ: XOMA)

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information, please read our full disclaimer at www.rdinvesting.com/disclaimer.


For any questions, inquiries, or comments reach out to us directly at:


Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011



CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com